COVID-19 vaccination: The road ahead
DM Altmann, RJ Boyton - Science, 2022 - science.org
A diverse array of successful, first-generation SARS-CoV-2 vaccines have played a huge
role in efforts to bring the COVID-19 pandemic under control, even though inequitable …
role in efforts to bring the COVID-19 pandemic under control, even though inequitable …
Overview of the main anti-SARS-CoV-2 vaccines: mechanism of action, efficacy and safety
MT Mascellino, F Di Timoteo… - Infection and drug …, 2021 - Taylor & Francis
This review takes into consideration the principal vaccines developed against the SARS-
CoV-2 in this unprecedented period of Covid-19 pandemic. We evaluated the mechanism of …
CoV-2 in this unprecedented period of Covid-19 pandemic. We evaluated the mechanism of …
Immune boosting by B. 1.1. 529 (Omicron) depends on previous SARS-CoV-2 exposure
The Omicron, or Pango lineage B. 1.1. 529, variant of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) carries multiple spike mutations with high transmissibility and …
coronavirus 2 (SARS-CoV-2) carries multiple spike mutations with high transmissibility and …
[HTML][HTML] Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million …
U Agrawal, S Bedston, C McCowan, J Oke, L Patterson… - The Lancet, 2022 - thelancet.com
Background Current UK vaccination policy is to offer future COVID-19 booster doses to
individuals at high risk of serious illness from COVID-19, but it is still uncertain which groups …
individuals at high risk of serious illness from COVID-19, but it is still uncertain which groups …
[HTML][HTML] Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study
Summary Background The Pfizer-BioNTech (BNT162b2) and the Oxford-AstraZeneca
(ChAdOx1 nCoV-19) COVID-19 vaccines have shown excellent safety and efficacy in phase …
(ChAdOx1 nCoV-19) COVID-19 vaccines have shown excellent safety and efficacy in phase …
Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2
JE Ebinger, J Fert-Bober, I Printsev, M Wu, N Sun… - Nature medicine, 2021 - nature.com
In a cohort of BNT162b2 (Pfizer–BioNTech) mRNA vaccine recipients (n= 1,090), we
observed that spike-specific IgG antibody levels and ACE2 antibody binding inhibition …
observed that spike-specific IgG antibody levels and ACE2 antibody binding inhibition …
Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine
Extension of the interval between vaccine doses for the BNT162b2 mRNA vaccine was
introduced in the United Kingdom to accelerate population coverage with a single dose. At …
introduced in the United Kingdom to accelerate population coverage with a single dose. At …
Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine rollout has
coincided with the spread of variants of concern. We investigated whether single-dose …
coincided with the spread of variants of concern. We investigated whether single-dose …
[HTML][HTML] Reduced risk of reinfection with SARS-CoV-2 after COVID-19 vaccination—Kentucky, May–June 2021
AM Cavanaugh - MMWR. Morbidity and mortality weekly report, 2021 - cdc.gov
Discussion This study found that among Kentucky residents who were previously infected
with SARS-CoV-2 in 2020, those who were unvaccinated against COVID-19 had …
with SARS-CoV-2 in 2020, those who were unvaccinated against COVID-19 had …
[HTML][HTML] COVID-19 vaccine challenges: What have we learned so far and what remains to be done?
Abstracts Developing and distributing a safe and effective SARS-CoV-2 (COVID-19) vaccine
has garnered immense global interest. Less than a year after COVID-19 was declared a …
has garnered immense global interest. Less than a year after COVID-19 was declared a …